222 related articles for article (PubMed ID: 26780071)
1. [Platinum antitumor complexes].
Bonetti A; Giuliani J; Muggia F
Recenti Prog Med; 2015 Dec; 106(12):618-28. PubMed ID: 26780071
[TBL] [Abstract][Full Text] [Related]
2. Platinum compounds in children with cancer: toxicity and clinical management.
Ruggiero A; Trombatore G; Triarico S; Arena R; Ferrara P; Scalzone M; Pierri F; Riccardi R
Anticancer Drugs; 2013 Nov; 24(10):1007-19. PubMed ID: 23962902
[TBL] [Abstract][Full Text] [Related]
3. Comparative antitumour activity of cisplatin and two new cisplatin-analogues JM8 and JM9 in human testicular carcinoma xenografts.
Harstrick A; Casper J; Schmoll HJ
Int J Androl; 1987 Feb; 10(1):139-45. PubMed ID: 3034790
[TBL] [Abstract][Full Text] [Related]
4. Growth and chemotherapy of a human germ-cell tumour line (GCT 27).
Schlappack OK; Bush C; Delic JI; Steel GG
Strahlenther Onkol; 1989 Jul; 165(7):541. PubMed ID: 2473535
[No Abstract] [Full Text] [Related]
5. Cardiovascular events in survivors of high-dose chemotherapy for germ cell tumors.
Ishioka J; Fujii Y; Kageyama Y; Fukuda H; Higashi Y; Kihara K
Int J Urol; 2008 Jul; 15(7):642-5. PubMed ID: 18643784
[TBL] [Abstract][Full Text] [Related]
6. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
Kollmannsberger C; Rick O; Derigs HG; Schleucher N; Schöffski P; Beyer J; Schoch R; Sayer HG; Gerl A; Kuczyk M; Spott C; Kanz L; Bokemeyer C
J Clin Oncol; 2002 Apr; 20(8):2031-7. PubMed ID: 11956262
[TBL] [Abstract][Full Text] [Related]
7. High-Dose Chemotherapy in a Late Relapse, Platinum-Refractory Nonseminomatous Germ Cell Tumor.
Connell BJ; Patel MJ; Tretter CG
Clin Genitourin Cancer; 2016 Aug; 14(4):e441-3. PubMed ID: 27055370
[No Abstract] [Full Text] [Related]
8. Toxicity of platinum compounds.
Hartmann JT; Lipp HP
Expert Opin Pharmacother; 2003 Jun; 4(6):889-901. PubMed ID: 12783586
[TBL] [Abstract][Full Text] [Related]
9. cis-Diammine-1, 1-cyclobutane dicarboxylate platinum II (carboplatin) in the treatment of testicular germ-cell tumours: a preliminary report.
Peckham MJ; Horwich A; Brada M; Drury A; Hendry WF
Cancer Treat Rev; 1985 Sep; 12 Suppl A():101-10. PubMed ID: 3002622
[TBL] [Abstract][Full Text] [Related]
10. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
[TBL] [Abstract][Full Text] [Related]
11. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of carboplatin in patients with advanced germ cell tumors refractory to cisplatin.
Motzer RJ; Bosl GJ; Tauer K; Golbey R
Cancer Treat Rep; 1987 Feb; 71(2):197-8. PubMed ID: 3026627
[TBL] [Abstract][Full Text] [Related]
13. Toxicities of the platinum antineoplastic agents.
Markman M
Expert Opin Drug Saf; 2003 Nov; 2(6):597-607. PubMed ID: 14585068
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in management of patients with platinum-refractory testicular germ cell tumors.
Kollmannsberger C; Nichols C; Bokemeyer C
Cancer; 2006 Mar; 106(6):1217-26. PubMed ID: 16463389
[TBL] [Abstract][Full Text] [Related]
15. New developments and approaches in the platinum arena.
Judson I; Kelland LR
Drugs; 2000; 59 Suppl 4():29-36; discussion 37-8. PubMed ID: 10864228
[TBL] [Abstract][Full Text] [Related]
16. Platinum-refractory germ cell tumors: an update on current treatment options and developments.
Oing C; Alsdorf WH; von Amsberg G; Oechsle K; Bokemeyer C
World J Urol; 2017 Aug; 35(8):1167-1175. PubMed ID: 27449639
[TBL] [Abstract][Full Text] [Related]
17. [Antitumor effect of JM-8 (a cisplatin analogue) on testicular cancer cells in vitro and in vivo].
Hashimura T; Okada K; Yoshida O
Gan To Kagaku Ryoho; 1985 May; 12(5):1137-42. PubMed ID: 3888118
[TBL] [Abstract][Full Text] [Related]
18. Is it time to discontinue using high-dose chemotherapy for salvage of patients with advanced germ-cell tumors failing first-line platinum chemotherapy?
Oyan B; Koc Y
Ann Oncol; 2006 Feb; 17(2):349-50. PubMed ID: 16166174
[No Abstract] [Full Text] [Related]
19. [The role of chemotherapy in the treatment of testicular cancer with the exception of seminomas].
Kenis Y; Piccart M; Beer M
Rev Med Brux; 1983 Apr; 4(4):219-23. PubMed ID: 6192477
[No Abstract] [Full Text] [Related]
20. Influence of vitamin D on cisplatin sensitivity in testicular germ cell cancer-derived cell lines and in a NTera2 xenograft model.
Jørgensen A; Blomberg Jensen M; Nielsen JE; Juul A; Rajpert-De Meyts E
J Steroid Biochem Mol Biol; 2013 Jul; 136():238-46. PubMed ID: 23098692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
